Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | GPER1 | Q99527 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403736 | 0.88 | MKNK1 (0.35) | MKNK1MKNK2BRD4CREBBPGPER1 | |
| SCHEMBL28403738 | 0.88 | MKNK1 (0.35) | MKNK1MKNK2BRD4CREBBPGPER1 | |
| SCHEMBL30557222 | 0.86 | BRD4 (0.35) | MKNK1MKNK2BRD4CREBBPEP300 | |
| SCHEMBL20908298 | 0.83 | FGFR1 (0.34) | HSP90AA1 | |
| SCHEMBL21148868 | 0.83 | FGFR1 (0.34) | HSP90AA1 | |
| SCHEMBL20907580 | 0.83 | JAK1 (0.36) | MKNK1MKNK2BRD4CREBBPEP300 | |
| SCHEMBL21150362 | 0.83 | JAK1 (0.36) | MKNK1MKNK2BRD4CREBBPEP300 | |
| SCHEMBL29640359 | 0.82 | MKNK1 (0.32) | MKNK1MKNK2BRD4CREBBPEP300 | |
| SCHEMBL20908223 | 0.82 | MKNK1 (0.32) | MKNK1MKNK2BRD4CREBBPEP300 | |
| SCHEMBL23115147 | 0.78 | POLQ (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | MKNK1 881/4885MKNK2 1707/4885BRD4 1637/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | MKNK1 778/4885MKNK2 1358/4885BRD4 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.